CD19 and diffuse large B-cell lymphoma: Nonetheless, infusion of the axicabtagene ciloleucel to 111 participants with diffuse large B cell lymphoma (DLBCL) at the dosage of 2 × 106 CD19-CAR-T cells/kg displayed significant efficacy.